On May 24, 2022 Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, reported that Avani Kanubaddi, President and Chief Operating Officer of Enveric, will participate virtually in Microdose’s Psychedelic Capital: May 2022 Conference to be held virtually on May 26, 2022 (Press release, Enveric Biosciences, MAY 24, 2022, View Source [SID1234614977]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Kanubaddi will participate on a panel "The Spinoffs – Divide and Conquer" on Thursday, May 26th at 4:05 p.m. ET. The panel will discuss the latest spinoffs among publicly traded companies to stay competitive, honor the shareholders and combat the markets. Register to attend here.

For more information about the conference, or to schedule a one-on-one meeting with Enveric’s management team, please send an email to KCSA Strategic Communications at [email protected].